Cello Health PLC Director/PDMR Shareholding (6335T)

TIDMCLL

RNS Number : 6335T

Cello Health PLC

21 March 2019

Cello Health plc

("Cello" or the "Group")

Director/PDMR Shareholding

The Group provides the following notification in accordance with Article 19(3) of the Market Abuse Regulation:

 
 1     Details of the person discharging managerial responsibilities 
        / person closely associated 
 a)    Name                                   Alasdair Combe 
      -------------------------------------  ---------------------------------------------- 
 2     Reason for the notification 
      ------------------------------------------------------------------------------------- 
 a)    Position/status                        Person closely associated with Jane 
                                               Shirley, Joint CEO of Cello Health 
                                               Insight and CEO of Cello Health Europe 
      -------------------------------------  ---------------------------------------------- 
 b)    Initial notification                   Initial notification 
        /Amendment 
      -------------------------------------  ---------------------------------------------- 
 3     Details of the issuer, emission allowance market participant, 
        auction platform, auctioneer or auction monitor 
      ------------------------------------------------------------------------------------- 
 a)    Name                                   Cello Health plc 
      -------------------------------------  ---------------------------------------------- 
 b)    LEI                                    2138004TZYGZLWQP7N64 
      -------------------------------------  ---------------------------------------------- 
 4     Details of the transaction(s): section to be repeated 
        for (i) each type of instrument; (ii) each type of transaction; 
        (iii) each date; and (iv) each place where transactions 
        have been conducted 
      ------------------------------------------------------------------------------------- 
 a)    Description of the                     Ordinary shares of 10 pence each 
        financial instrument, 
        type of instrument 
       Identification code                    ISIN: GB00B0310763 
      -------------------------------------  ---------------------------------------------- 
 b)    Nature of the transaction              Purchase of ordinary shares 
      -------------------------------------  ---------------------------------------------- 
 c)    Price(s) and volume(s) 
                                              ------------------------  ----------------- 
                                               Price(s)                  Volume(s) 
                                              ------------------------  ----------------- 
    122.5 pence                                                          5,000 
   -------------------------------------------------------------------  ----------------- 
 
 d)    Aggregated information 
  - Aggregated volume                    5,000 
  - Price                                GBP6,125.00 
 -------------------------------------  --------------------------------------------------- 
 e)    Date of the transaction                21 March 2019 
      -------------------------------------  ---------------------------------------------- 
 f)    Place of the transaction               AIMX 
      -------------------------------------  ----------------------------------------------

Enquiries:

 
 Cello Health plc                  020 7812 8460 
 Mark Scott, Chief Executive 
 Mark Bentley, Finance Director 
 
 Cenkos Securities plc             0207 397 8900 
 Mark Connelly 
  Harry Hargreaves

Notes to Editors

Cello Health plc is a global healthcare-focused advisory Group comprised of a set of leading clinical, commercial advisory and digital delivery capabilities. Cello Health plc currently services 24 of the top 25 pharmaceutical clients globally, as well as a wide range of biotech, diagnostics, devices and other key non-healthcare clients.

Cello Health plc enables clients to commercialise and differentiate their assets and drive brand success in ever more complex global markets. The business delivers its services through nearly 1,000 highly skilled professionals, utilising latest thinking, technology and digital solutions.

Cello Health plc delivers its services from an office network in the UK, USA, and Asia, with hub offices in New York City, Philadelphia PA, London, Edinburgh, Farnham and Cheltenham.

For further information, please visit: https://cellohealthplc.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

DSHCKDDKPBKDFNB

(END) Dow Jones Newswires

March 21, 2019 11:10 ET (15:10 GMT)

Cello Health (LSE:CLL)
Historical Stock Chart
From Jul 2024 to Aug 2024